Association between surgical risk and 30‐day stroke after transcatheter versus surgical aortic valve replacement: a systematic review and meta‐analysis. Issue 4 (25th June 2020)

• Record Type: Journal Article
• Authors: Matsuda, Yuji; Nai Fovino, Luca; Giacoppo, Daniele; Scotti, Andrea; Massussi, Mauro; Ueshima, Daisuke; Sasano, Tetsuo; Fabris, Tommaso; Tarantini, Giuseppe
• Is Part Of: Catheterization and cardiovascular interventions. Volume 97:Issue 4(2021)
• Page Start: E536
• Page End: E543
• Publication Date: 2020-06-25
• Subjects: cerebrovascular accident -- stroke -- surgical aortic valve replacement -- surgical risk -- transcatheter aortic valve replacement; Heart -- Diseases -- Diagnosis -- Periodicals; Cardiac catheterization -- Periodicals; 616.1207572
• DOI: 10.1002/ccd.29105
• Languages: English
• ISSNs: 1522-1946

Abstract

Abstract: Background: Stroke is a feared complication of transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR). Objectives: With this meta‐analysis we aimed to evaluate the incidence of 30‐day stroke with TAVR and SAVR focusing on its possible correlation with surgical risk. Methods: Major electronic databases were searched for studies published between January 2002 and October 2019 reporting the rates of 30‐day stroke after TAVR and SAVR. Data were pooled using fixed‐ and random‐effects models. The primary outcome of the study was stroke rate within 30‐day from TAVR or SAVR. Results were stratified according to surgical risk score (high, intermediate and low). Results: A total of 23 studies were identified (TAVR: 14, 589 patients; SAVR: 11, 681 patients). Regardless of the model used, in the overall population TAVR was associated with a significant reduction in the risk of stroke compared with SAVR (fixed effect: OR 0.78, 95% CI 0.66–0.92, p = .003; random‐effects: OR 0.80, 95% CI 0.64–1.00, p = .045). Rates of 30‐day stroke after TAVR and SAVR were not significantly different in the high‐ (OR 1.01, 95% CI 0.44–1.98, p = .105) and intermediate‐risk groups (OR 0.92, 95% CI 0.63–1.36, p = .319), while low‐risk patients had a lower rate of 30‐day stroke after TAVR than SAVR (OR 0.65, 95% CI 0.50–0.83, p < .001). Meta‐regression showed a significant association between surgical risk score and 30‐day stroke rate ( p = .007). Conclusions: TAVR is associated with a lower risk of 30‐day stroke compared with SAVR, mainly as a result of the significant advantage observed in patients at low surgical risk.